Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Francis Karanu"'
Autor:
Amy Wysong, Priscilla Ortiz, Douglas Bittel, Lindsey Ott, Francis Karanu, Michael Filla, Lisa Stehno-Bittel
Publikováno v:
BMC Veterinary Research, Vol 17, Iss 1, Pp 1-12 (2021)
Abstract Background The source of multipotent stromal cells (MSC) can have a significant influence on the health and expansion capacity of the cells. As the applications for allogeneic MSCs in the treatment of feline diseases increase, the location o
Externí odkaz:
https://doaj.org/article/9fa8f755e85c4224ade263bc05953d55
Autor:
Stephen Harrington, Francis Karanu, Karthik Ramachandran, S. Janette Williams, Lisa Stehno-Bittel
Publikováno v:
PLoS ONE, Vol 17, Iss 5 (2022)
Background Protection of islets without systemic immunosuppression has been a long-sought goal in the islet transplant field. We conducted a pilot biocompatibility/safety study in healthy dogs followed by a dose-finding efficacy study in diabetic dog
Externí odkaz:
https://doaj.org/article/712853bddfdb47b0a33641b4bc207c5c
Publikováno v:
Tissue Engineering. Part A
Cell microencapsulation is a rapidly expanding field with broad potential for stem cell therapies and tissue engineering research. Traditional alginate microspheres suffer from poor biocompatibility, and microencapsulation of more advanced hydrogels
Autor:
Stephen Harrington, Francis Karanu, Karthik Ramachandran, S. Janette Williams, Lisa Stehno-Bittel
Publikováno v:
PloS one. 17(5)
BackgroundProtection of islets without systemic immunosuppression has been a long-sought goal in the islet transplant field. We conducted a pilot biocompatibility/safety study in healthy dogs followed by a dose-finding efficacy study in diabetic dogs
Autor:
Priscilla Ortiz, Michael Filla, Francis Karanu, Lisa Stehno-Bittel, Lindsey Ott, Amy Wysong, Douglas C. Bittel
Publikováno v:
BMC Veterinary Research
BMC Veterinary Research, Vol 17, Iss 1, Pp 1-12 (2021)
BMC Veterinary Research, Vol 17, Iss 1, Pp 1-12 (2021)
Background The source of multipotent stromal cells (MSC) can have a significant influence on the health and expansion capacity of the cells. As the applications for allogeneic MSCs in the treatment of feline diseases increase, the location of the ini
Autor:
Francis Karanu, Lindsey Ott, Stephen Harrington, Susan J. Williams, Aldyn Wildey, Megan Hamilton
Publikováno v:
Diabetes. 69
FDA approved Clinical Trials are already under way using stem cell-derived insulin-producing cells (IPCs) for the treatment of type 1 diabetes in humans. Differentiation methods used to derive beta-cell like IPCs have greatly improved over the last f
Publikováno v:
Diabetes. 68
Cell microencapsulation associated with islet transplantation is a rapidly expanding field. Traditional alginate microspheres still suffer from poor biocompatibility, and microencapsulation of more advanced hydrogels is challenging due to their slowe
Autor:
Jean Xu, Timothy J. Kieffer, Ali Asadi, Ziliang Ao, Garth L. Warnock, Alireza Rezania, Jennifer E. Bruin, Francis Karanu, Rebecca Gauvin, Kavitha Narayan, Michael J. Riedel, John J. O'Neil, Majid Mojibian
Publikováno v:
Diabetes
Diabetes is a chronic debilitating disease that results from insufficient production of insulin from pancreatic β-cells. Islet cell replacement can effectively treat diabetes but is currently severely limited by the reliance upon cadaveric donor tis
Autor:
Garth L. Warnock, Timothy J. Kieffer, Alireza Rezania, Ziliang Ao, Francis Karanu, Michael J. Riedel, Rhonda D. Wideman
Publikováno v:
Diabetes
OBJECTIVE Differentiation of human embryonic stem (hES) cells to fully developed cell types holds great therapeutic promise. Despite significant progress, the conversion of hES cells to stable, fully differentiated endocrine cells that exhibit physio
Autor:
Blair K. Gage, Rhonda D. Wideman, Travis D. Webber, Alireza Rezania, Michael J. Riedel, Timothy J. Kieffer, Robert K. Baker, Yukihiro Fujita, Francis Karanu
Publikováno v:
Differentiation. 80:130-139
Islet transplantation represents a potential cure for type 1 diabetes; however, a lack of sufficient donor material limits its clinical use. To address the shortfall of islet availability, surrogate insulin-producing cells are sought. Studies suggest